The implications of enterococci for the intensive care unit

Crit Care Resusc. 2007 Mar;9(1):69-75.

Abstract

Objective: To review the evidence of pathogenicity and virulence of Enterococcus spp. in the intensive care unit.

Data sources: MEDLINE search for studies and articles on Enterococcus spp.

Results: Enterococcus spp. are normal commensal organisms in the alimentary tract and are traditionally considered to have relatively low virulence. However, they can cause a variety of life-threatening infections, especially in immunocompromised patients and nosocomial settings. The role of enterococci as primary pathogens in polymicrobial intra-abdominal infections remains controversial. There is enough evidence to suggest that complicated, community-acquired intra-abdominal infections involving mixed flora can be treated with surgery and non-enterococcal antibiotic cover. Recent studies have shown that enterococcal peritonitis is associated with increased mortality.

Conclusions: Although the prevalence of enterococcal infections may be low in Australian ICUs, these infections are associated with a higher prevalence of treatment failure and mortality. We therefore suggest the use of enterococcal antibiotic coverage in: immunocompromised patients with a high risk of bacteraemia (eg, liver transplant patients); patients with peritonitis and valvular heart disease or prosthetic intravascular material; patients with severe sepsis of abdominal origin who have previously received broad spectrum antibiotics; and patients with persistent intra- abdominal collection without clinical improvement.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Aminoglycosides / pharmacology
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Clindamycin / pharmacology
  • Cross Infection* / drug therapy
  • Cross Infection* / microbiology
  • Cross Infection* / prevention & control
  • Drug Resistance, Bacterial
  • Enterococcus* / drug effects
  • Enterococcus* / isolation & purification
  • Gram-Positive Bacterial Infections* / drug therapy
  • Gram-Positive Bacterial Infections* / epidemiology
  • Humans
  • Immunocompromised Host
  • Infection Control
  • Intensive Care Units*
  • Peritonitis / microbiology
  • Risk Factors
  • Vancomycin / pharmacology
  • Vancomycin / therapeutic use
  • beta-Lactams / pharmacology

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • beta-Lactams
  • Clindamycin
  • Vancomycin